Ensol Biosciences (XKRX:140610) Change In Working Capital : ₩132.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Change In Working Capital?

Ensol Biosciences's change in working capital for the quarter that ended in Dec. 2023 was ₩132.0 Mil.

Ensol Biosciences's change in working capital for the fiscal year that ended in Dec. 2023 was ₩132.0 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Ensol Biosciences Change In Working Capital Historical Data

The historical data trend for Ensol Biosciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Change In Working Capital Chart

Ensol Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-325.33

-50.70

-580.68

-48.98

132.02

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Change In Working Capital	Get a 7-Day Free Trial					-325.33	-50.70	-580.68	-48.98	132.02

Ensol Biosciences Change In Working Capital Calculation

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was ₩132.0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Ensol Biosciences Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines